Enhancing Healthcare M&A Valuations Using Probabilistic Sensitivity Analysis

Abstract

Healthcare mergers and acquisitions (M&A) create strategic pathways for companies to advance product development, streamline integration, and drive innovation. Accurate valuation, therefore, lies at the heart of corporate strategic and financial decision-making, with different methodologies applied based on the nature of the transaction. Although existing valuation frameworks are flexible, dynamic, and widely adopted, the precision of healthcare company valuations is heavily impacted by factors such as regulatory frameworks, integration risks, reimbursement shifts, policy changes, and patient outcomes. Probabilistic Sensitivity Analysis (PSA) addresses some of these challenges by evaluating how uncertainty in input parameters affects valuation results through assigning probability distributions to those inputs, rather than relying on single-point estimates. This article explores the benefits of incorporating PSA into the valuation of healthcare companies and evaluates how PSA can enhance the reliability, transparency, and adaptability of traditional valuation approaches. We will specifically focus on comparing deterministic models with probabilistic methods such as Monte Carlo simulations, decision trees, and Bayesian frameworks. The paper further highlights real-world applications, critiques limitations, and identifies future research opportunities. We believe that integrating PSA into valuation processes for M&A transactions enables policymakers, acquirers, and healthcare investors to better navigate the complexities of high-risk M&A environments through promoting more informed and data-driven decision-making. We believe that PSA serves not only as a methodological enhancement but also as a strategic tool that bolsters stakeholder confidence and post-acquisition performance within an ever-changing healthcare landscape.